公司资料
Mustang Bio 股价、新闻与催化剂
- 股票代码:
- MBIO
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.55 USD (+1.91%)
收盘价
最后更新: 2026年9月21日
5.77M USD
市值
股价为何变动
截至 2026年9月21日，MBIO 上涨 1.91%，收于 $0.5500。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Mustang Bio is a cell and gene therapy company focused on oncology, including CAR-T and other engineered cell approaches. Its story is built around the possibility that targeted cell therapies can create differentiated outcomes in hard-to-treat cancers.
所在地与行业分类
Mustang Bio is headquartered in the United States and listed on NASDAQ, placing it in the small-cap oncology biotech universe. It sits squarely in development-stage cell therapy rather than commercial large-cap pharma.
商业模式特征
The company depends on clinical data, manufacturing execution, and access to capital to keep programs moving. Investors usually focus on trial updates, safety and efficacy signals, and whether the platform can survive long enough to reach meaningful commercialization.
生物医药行业定位
Mustang Bio occupies a high-volatility cell therapy niche within biotech. Because it is still heavily development-driven, the stock tends to respond sharply to readouts, financing, and strategic partnerships.
未来催化剂
- Mustang Bio’s catalysts are its cell-therapy pipeline, especially any update that clarifies whether the CAR-T and gene-therapy assets still have enough momentum. The stock remains highly data-sensitive.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。